109 related articles for article (PubMed ID: 19665041)
61. Molecular pathways: human leukocyte antigen G (HLA-G).
Curigliano G; Criscitiello C; Gelao L; Goldhirsch A
Clin Cancer Res; 2013 Oct; 19(20):5564-71. PubMed ID: 23897901
[TBL] [Abstract][Full Text] [Related]
62. Nitric oxide produces HLA-G nitration and induces metalloprotease-dependent shedding creating a tolerogenic milieu.
Díaz-Lagares A; Alegre E; LeMaoult J; Carosella ED; González A
Immunology; 2009 Mar; 126(3):436-45. PubMed ID: 18764882
[TBL] [Abstract][Full Text] [Related]
63. Up-regulation of human leukocyte antigen G expression in primary cutaneous malignant melanoma associated with host-vs-tumor immune response.
Fang X; Zhang X; Li J
J Huazhong Univ Sci Technolog Med Sci; 2008 Apr; 28(2):219-21. PubMed ID: 18481003
[TBL] [Abstract][Full Text] [Related]
64. The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture.
Klein B; Loven D; Lurie H; Rakowsky E; Nyska A; Levin I; Klein T
J Neurosurg; 1994 Jun; 80(6):1074-7. PubMed ID: 8189262
[TBL] [Abstract][Full Text] [Related]
65. HLA-G as an Inhibitor of Immune Responses.
Lin A; Yan WH
Methods Mol Biol; 2016; 1371():3-9. PubMed ID: 26530791
[TBL] [Abstract][Full Text] [Related]
66. HLA-G expression in melanomas.
Marletta S; Girolami I; Munari E; Pantanowitz L; Bernasconi R; Torresani E; Brunelli M; Eccher A
Int Rev Immunol; 2021; 40(5):330-343. PubMed ID: 33426980
[TBL] [Abstract][Full Text] [Related]
67. [Human leukocyte antigen-G (HLA)-G as a biomarker in cancer].
Porras-Dorantes Á; García-Ortiz JE
Gac Med Mex; 2014 Dec; 150 Suppl 2():138-9. PubMed ID: 25643772
[TBL] [Abstract][Full Text] [Related]
68. [The HLA (human leukocyte antigen) system].
Scripcaru G; Pleşa M
Rev Med Chir Soc Med Nat Iasi; 1978; 82(2):185-9. PubMed ID: 705112
[No Abstract] [Full Text] [Related]
69. Human Leukocyte antigen-G (HLA-G) and gastrointestinal malignancy.
Nazemalhosseini-Mojarad E; Kuppen PJ; Zali MR
Gastroenterol Hepatol Bed Bench; 2014; 7(2):79-81. PubMed ID: 24834297
[No Abstract] [Full Text] [Related]
70. Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer.
Fisher JG; Doyle ADP; Graham LV; Khakoo SI; Blunt MD
Vaccines (Basel); 2022 Nov; 10(12):. PubMed ID: 36560403
[TBL] [Abstract][Full Text] [Related]
71. HLA-E and HLA-F Are Overexpressed in Glioblastoma and HLA-E Increased After Exposure to Ionizing Radiation.
Hrbac T; Kopkova A; Siegl F; Vecera M; Ruckova M; Kazda T; Jancalek R; Hendrych M; Hermanova M; Vybihal V; Fadrus P; Smrcka M; Sokol F; Kubes V; Lipina R; Slaby O; Kren L; Sana J
Cancer Genomics Proteomics; 2022; 19(2):151-162. PubMed ID: 35181585
[TBL] [Abstract][Full Text] [Related]
72. Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response.
Toffoli EC; Sheikhi A; Höppner YD; de Kok P; Yazdanpanah-Samani M; Spanholtz J; Verheul HMW; van der Vliet HJ; de Gruijl TD
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572396
[TBL] [Abstract][Full Text] [Related]
73. Radiotherapy in combination with systemic therapies for brain metastases: current status and progress.
Liu L; Chen W; Zhang R; Wang Y; Liu P; Lian X; Zhang F; Wang Y; Ma W
Cancer Biol Med; 2020 Nov; 17(4):910-922. PubMed ID: 33299643
[TBL] [Abstract][Full Text] [Related]
74. Immunomodulation of NK Cells by Ionizing Radiation.
Chen J; Liu X; Zeng Z; Li J; Luo Y; Sun W; Gong Y; Zhang J; Wu Q; Xie C
Front Oncol; 2020; 10():874. PubMed ID: 32612950
[TBL] [Abstract][Full Text] [Related]
75. Immune targets in the tumor microenvironment treated by radiotherapy.
Ozpiskin OM; Zhang L; Li JJ
Theranostics; 2019; 9(5):1215-1231. PubMed ID: 30867826
[TBL] [Abstract][Full Text] [Related]
76. HLA-G Expression in Tumor Tissues and Soluble HLA-G Plasma Levels in Patients with Gastrointestinal Cancer.
Farjadian S; Tabebordbar M; Mokhtari M; Safaei A; Malekzadeh M; Ghaderi A
Asian Pac J Cancer Prev; 2018 Oct; 19(10):2731-2735. PubMed ID: 30360598
[TBL] [Abstract][Full Text] [Related]
77. HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma.
De Re V; Caggiari L; Mussolin L; d'Amore ES; Famengo B; De Zorzi M; Martina L; Elia C; Pillon M; Santoro N; Muggeo P; Buffardi S; Bianchi M; Sala A; Farruggia P; Vinti L; Carosella ED; Burnelli R; Mascarin M
Oncotarget; 2017 Dec; 8(62):105957-105970. PubMed ID: 29285306
[TBL] [Abstract][Full Text] [Related]
78. Cancer treatment and the KIR-HLA system: an overview.
Leone P; De Re V; Vacca A; Dammacco F; Racanelli V
Clin Exp Med; 2017 Nov; 17(4):419-429. PubMed ID: 28188495
[TBL] [Abstract][Full Text] [Related]
79. HLA-G regulators in cancer medicine: an outline of key requirements.
Zidi I; Ben Amor N
Tumour Biol; 2011 Dec; 32(6):1071-86. PubMed ID: 21792710
[TBL] [Abstract][Full Text] [Related]
80. Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer.
Allard M; Oger R; Vignard V; Percier JM; Fregni G; Périer A; Caignard A; Charreau B; Bernardeau K; Khammari A; Dréno B; Gervois N
PLoS One; 2011; 6(6):e21118. PubMed ID: 21712991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
